Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma

Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma

To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL). Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m(2) and anti-CD20 rituximab 375 mg/m(2) monoclonal antibodies weekly...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 23; no. 22; pp. 5044 - 5051
Main Authors: LEONARD, John P, COLEMAN, Morton, KOVACS, Jacqueline, DING, Cliff L, WEGENER, William A, HORAK, Ivan D, GOLDENBERG, David M, KETAS, Jamie, ASHE, Michelle, FIORE, Jennifer M, FURMAN, Richard R, NIESVIZKY, Ruben, SHORE, Tsiporah, CHADBURN, Amy, HOME, Heather
Format: Journal Article
Language:English
Published: Baltimore, MD American Society of Clinical Oncology 01-08-2005
Lippincott Williams & Wilkins
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Female
Hematologic and hematopoietic diseases
Humans
Infusions, Intravenous
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - pathology
Male
Medical sciences
Middle Aged
Recurrence
Rituximab
Treatment Outcome
Tumors
Epratuzumab
Relapse
Treatment resistance
Cancerology
Lymphoproliferative syndrome
Immunotherapy
Anticytokine
Rituximab
Malignant hemopathy
Combined treatment
Monoclonal antibody
Non Hodgkin lymphoma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL). Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m(2) and anti-CD20 rituximab 375 mg/m(2) monoclonal antibodies weekly for four doses each. Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]). Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores. Patients with DLBCL had a median of three (range, one to eight) prior regimens (14% resistant to last treatment) and 71% had high intermediate-risk or high-risk International Prognostic Index scores. All patients were rituximab naïve. Treatment was well tolerated, with toxicities principally infusion-related and predominantly grade 1 or 2. Ten (67%) patients with follicular NHL achieved an objective response (OR), including nine of 15 (60%) with complete responses (CRs and unconfirmed CRs). Four of six assessable patients (67%) with DLBCL achieved an OR, including three (50%) CRs. Median time to progression for all indolent NHL patients was 17.8 months. The full-dose combination of epratuzumab with rituximab was well tolerated and had significant clinical activity in NHL, suggesting that this combination should be tested in comparison with single-agent treatment.
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2005.13.821